NeuroSense Therapeutics (NRSN) 20-F14 Apr 222021 FY Annual report (foreign)Financial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	12 Months Ended
Document And Entity Information - shares	Dec. 31, 2021	Apr. 13, 2022
Document Information Line Items
Entity Registrant Name	NeuroSense Therapeutics Ltd.
Trading Symbol	NRSN
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		10,943,534
Amendment Flag	false
Entity Central Index Key	0001875091
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41084
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	11 HaMenofim Street
Entity Address, Address Line Two	Building B
Entity Address, City or Town	Herzliya
Entity Address, Postal Zip Code	562
Entity Address, Country	IL
Title of 12(b) Security	Ordinary Shares, no par value per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	1057
Auditor Name	Somekh Chaikin
Auditor Location	Tel-Aviv, Israel
Business Contact
Document Information Line Items
Entity Address, Address Line One	11 HaMenofim Street
Entity Address, Address Line Two	Building B
Entity Address, City or Town	Herzliya
Entity Address, Postal Zip Code	562
Entity Address, Country	IL
Contact Personnel Name	Or Eisenberg
City Area Code	+972
Local Phone Number	9-7996183

Statements of Financial Positio

Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 11,063	$ 699
Other receivables	310	30
Restricted deposits	39	37
Total current assets	11,412	766
Property, plant and equipment, net	19	13
Total non-current assets	19	13
Total assets	11,431	779
Current liabilities:
Trade payables	39	55
Other payables	558	65
Total current liabilities	597	120
Non Current liabilities:
Liability in respect of warrants	1,828
Total non- current liabilities	1,828
Total liabilities	2,425	120
Shareholders’ equity:
Ordinary shares
Share premium and capital reserve	17,452	5,064
Accumulated deficit	(8,446)	(4,405)
Total shareholders’ equity	9,006	659
Total liabilities and shareholders’ equity	$ 11,431	$ 779

Statements of Income and Compre

Statements of Income and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Profit or loss [abstract]
Research and development expenses	$ (3,082)	$ (2,495)	$ (898)
General and administrative expenses	(2,505)	(393)	(337)
Operating loss	(5,587)	(2,888)	(1,235)
Financing expenses	(1,186)	(1)	(5)
Financing income	2,732	61	18
Total financing income, net	1,546	60	13
Net loss and comprehensive loss	$ (4,041)	$ (2,828)	$ (1,222)
Basic and diluted net loss per share (in Dollars per share)	$ (0.65)	$ (0.51)	$ (0.26)

Statements of Changes in Equity

Statements of Changes in Equity - USD ($) $ in Thousands	Ordinary Shares	Share Premium And Capital reserve	Accumulated Deficit	Total
Balance at Dec. 31, 2018		$ 464	$ (355)	$ 109
Balance (in Shares) at Dec. 31, 2018
Share based compensation		611		611
Net loss and comprehensive loss			(1,222)	(1,222)
Issuance of ordinary shares and warrants, net		1,420		1,420
Balance at Dec. 31, 2019		2,495	(1,577)	918
Balance (in Shares) at Dec. 31, 2019
Share based compensation		2,061		2,061
Issuance of ordinary shares, net		508		508
Net loss and comprehensive loss			(2,828)	(2,828)
Balance at Dec. 31, 2020		5,064	(4,405)	659
Balance (in Shares) at Dec. 31, 2020
Share based compensation		4,716		4,716
Issuance of SAFE instruments		800		800
Exercise of warrants and options		1,311		1,311
Issuance of ordinary shares, net upon IPO		5,561		5,561
Net loss and comprehensive loss			(4,041)	(4,041)
Balance at Dec. 31, 2021		$ 17,452	$ (8,446)	$ 9,006
Balance (in Shares) at Dec. 31, 2021

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss for the year	$ (4,041)	$ (2,828)	$ (1,222)
Adjustments for:
Depreciation	3	3		[1]
Share based compensation	4,159	2,061	611
Revaluation of liability in respect to warrants	(2,732)
Loss from disposal of property and equipment	8
Finance expense (income)	791	(2)
Increase in other receivables	(204)	(12)	(3)
Increase (decrease) in trade payables	(16)	32	23
Increase in other payables	493	51	9
Net cash used in operating activities	(1,539)	(695)	(582)
Cash flows from investing activities
Purchase of property, plant and equipment	(17)	(9)	(7)
Investment in restricted deposit			(19)
Net cash used in investing activities	(17)	(9)	(26)
Cash flows from financing activities
Repayment of loan from related party			(3)
Issuance of SAFE instruments	800
Exercise of warrants and options	1,238
Issuance of shares and warrants, net	9,864	508	1,420
Net cash provided by financing activities	11,902	508	1,417
Effects of exchange rate changes on cash and cash equivalents	18
Increase (decrease) in cash and cash equivalents	10,364	(196)	809
Cash and cash equivalents as at the beginning of the year	699	895	86
Cash and cash equivalents as of the end of the year	11,063	699	895
Non-cash activity
Exercise of options	$ 76

[1]	Less than 1 thousand.

General

General	12 Months Ended
General	Dec. 31, 2021
General [Abstract]
General	Note 1 — General A. NeuroSense Therapeutics Ltd. (“NeuroSense” or the “Company”) was incorporated in Israel on February 13, 2017. NeuroSense is a clinical-stage pharmaceutical company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is a novel oral formulation of a fixed dose combination composed of a specific ratio and doses of two FDA-approved drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer’s disease and Parkinson’s disease, with a similar strategy of combined products. The Company’s ordinary shares and warrants began trading on the Nasdaq Capital Market on December 9, 2021 under the ticker symbols "NRSN" and "NRSNW," respectively. B. The Company currently has no products approved for sale and the Company’s operations have been funded primarily by its shareholders. To date, the Company has generated no sales or revenues, has incurred losses and expects to incur significant additional losses due to the continuing focus on the research, development, clinical activities of its product candidates, preclinical programs, business development, organizational structure and to advance the programs within the Company’s pipeline. Consequently, its operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. The Company will require additional cash to fund the execution of its mid and long-term development program. The Company anticipates raising additional funds through public or private sales of debt or equity securities, collaborative arrangements, or some combination thereof. While management is progressing with its plans to secure external financing, there is no assurance that any such arrangement will be entered into or that financing will be available when needed in order to allow the Company to continue its operations, or if available, on terms favourable or acceptable to it. In the event financing is not obtained, the Company may pursue cost cutting measures or may be required to delay, reduce the scope of, or eliminate any of its development programs or clinical trials. These decisions could have a material adverse effect on the Company’s business. Based on its current expected level of operating expenditures, the Company’s cash resources as of December 31, 2021 and the additional funds raised subsequent to the reporting date from the exercise of warrants (see Note 18) will be sufficient to continue the development of the Company’s product for at least the next twelve months beyond the date of the filing date of the financial statements. C. In March 2020, the World Health Organization declared the outbreak of a new strain of coronavirus (COVID-19) a pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets, including in Israel. The pandemic has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter in place orders, and shutdowns. While the COVID-19 pandemic did not materially affect the Company’s financial results and business operations to date, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary. As of December 31, 2021, COVID-19 didn’t have material effect on Company’s operations.

Basis of Preparation

Basis of Preparation	12 Months Ended
Basis of Preparation	Dec. 31, 2021
Basis of Preparation [Abstract]
Basis of Preparation	Note 2 — Basis of Preparation A. Statement of Compliance The financial statements have been These financial statements were authorized for issuance by the board of directors of the Company on April 14, 2022. B. Basis of Measurement The financial statements have been prepared on the historical cost basis C. Functional and presentation currency These financial statements are presented in U.S. dollars (“$”), which is the Company’s functional currency. All amounts have been rounded to the nearest thousand, unless otherwise indicated. The U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to operate in the foreseeable future. Transactions in currencies other than the U.S. dollar are translated to the functional currency of the Company at exchange rates as of the date of each relevant transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest rates and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the relevant transaction. Foreign currency differences arising on translation are recognized in the statement of income as financing expenses or income. Below are details regarding the exchange rate of the New Israeli Shekel (“NIS”), the Euro and the GBP: Euro GBP NIS December 31, 2021 1.13 1.35 0.32 December 31, 2020 1.22 1.36 0.31 December 31, 2019 1.12 1.32 0.29 Change in percentages: Year ended December 31, 2021 (7.3 ) (0.73 ) 3.2 Year ended December 31, 2020 9.3 3.5 7.5 Year ended December 31, 2019 (2 ) 3.2 8.4 D. Operating Cycle The Company’s operating cycle is one year. E. Use of estimates and judgment The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The preparation of accounting estimates used in the preparation of the Company’s financial statements requires that management make assumptions regarding circumstances and events that involve considerable uncertainty. Company management prepares these estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized in the period in which the estimates are revised and in any future periods affected. Below is information about significant assumptions made by the Company’s management with respect to estimates and judgments: Share-based payment transactions Estimating fair value for share-based payment transactions requires a determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires a determination of the most appropriate inputs to the valuation model, including the fair value of the Company’s ordinary shares, the expected life of the share option, volatility, and related assumptions. For the measurement of the fair value of equity-settled transactions at the grant date and thereafter, the Company uses the Black-Scholes formula or the Binomial pricing model. In applying these options pricing models, before the Company's shares began trading on Nasdaq, the Company determined the fair value of its ordinary shares using different approaches. See Note 9 for further information. Fair value measurement of liability in respect of warrants Warrants that provide the holders with an option for cashless exercise are considered a derivative liability and are classified as financial liabilities at fair value through profit or loss. Accordingly, these warrants are measured at fair value and the changes in fair value in each reporting period are recognized in profit or loss. The fair values of these instruments at their issuance date were determined by using the Monte-Carlo model. Subsequent to issuance date, the fair value of the warrants are determined using the warrant price at the stock market. For information on details regarding fair value measurement at Level 2 and Level 1see Note 16 regarding financial instruments.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 3 — Significant Accounting Policies The accounting policies set out below have been applied consistently for all periods presented in these financial statements. A. Property, plant and equipment (1) Recognition and measurement Property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. Gain and loss on disposal of a property, plant and equipment item is determined by comparing the net proceeds from disposal with the carrying amount of the asset, and is recognized in profit or loss. (2) Subsequent costs The cost of replacing property, plant and equipment and other subsequent expenses are capitalized if it is probable that the future economic benefits associated with them will flow to the Company and their cost can be measured reliably. (3) Depreciation Depreciation is a systematic allocation of the depreciable amount of an asset over its useful life. The depreciable amount is the cost of the asset, or other amount substituted for cost, less its residual value. An asset is depreciated from the date it is ready for use, meaning the date it reaches the location and condition required for it to operate in the manner intended by management. Depreciation is recognized in profit or loss on a straight-line basis over the estimated useful lives of each part of the property, plant and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Annual depreciation rates are: % Computers and peripherals and equipment 33 Office furniture and equipment 7 – 15 Leasehold improvements The shorter of the lease term and the useful life Depreciation methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate. B. Financial instruments (1) Non-derivative financial assets Initial recognition of financial assets Financial assets are recognized initially on the trade date at which the Company becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Company to the cash flows from the asset expire, or the Company transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset were transferred. When the Company retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: amortized cost; fair value through other comprehensive income — investments in debt instruments; fair value through other comprehensive income — investments in equity instruments; or fair value through profit or loss. The Company has balances of other receivables and deposits that are held within a business model whose objective is collecting contractual cash flows. The contractual cash flows of these financial assets represent solely payments of principal and interest that reflect consideration for the time value of money and the credit risk. Accordingly, these financial assets are measured at amortized cost. The Company does not expect to incur any credit loss, thus the financial statements do not include provision for expected credit loss. Subsequent measurement and gains and losses Financial assets at amortized cost These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss. (2) Non-derivative financial liabilities Non-derivative financial liabilities include trade and other payables. Initial recognition of financial liabilities Financial liabilities are recognized initially on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Transaction costs directly attributable to an expected issuance of an instrument that will be classified as a financial liability are recognized as an asset in the framework of deferred expenses in the statement of financial position. These transaction costs are deducted from the financial liability upon its initial recognition or are amortized as financing expenses in the statement of profit or loss and when the issuance is no longer expected to occur. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Company, as specified in the agreement, expires or when it is discharged or cancelled. Offset of financial instruments Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Issuance of parcel of securities The consideration received from the issuance of a parcel of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the parcel, as described above. (3) Derivative financial liabilities Measurement of derivative financial instruments Derivatives are recognized initially at fair value. Attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognized in profit or loss, as financing income or expense. (4) Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity. C. Research and Development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures, including patent registration costs, are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. As of December 31, 2021, no development expenditures have met the recognition criteria and thus the Company expensed all of its development expenditures as incurred. D. Impairment of non-financial assets Assets that are subject to depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped together into the smallest group of assets that generates separately identifiable cash flows (cash-generating units). The carrying amounts of the Company’s non-financial assets reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. E. Employee benefits (1) Post-employment benefits The Company’s liability for severance pay for its employees is calculated pursuant to Israeli Severance Pay Law (1963) (the “Severance Pay Law”). The Company’s liability is covered by monthly deposits with severance pay funds and insurance policies. For all of the Company’s employees, the payments to pension funds and to insurance companies exempt the Company from any obligation towards its employees, in accordance with Section 14 of the Severance Pay Law, which is accounted for as a defined contribution plan. Accumulated amounts in pension funds and in insurance companies are not under the Company’s control or management and, accordingly, neither those amounts nor the corresponding accrual for severance pay are presented in the statements of financial position. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Contributions to a defined contribution plan that are due more than 12 months after the end of the period in which the employees render the service are discounted to their present value. (2) Share based payment The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at the grant date. The fair value is determined using an acceptable option pricing model. As for other service providers, the cost of each transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration for equity instruments cannot be measured, such goods or services are measured by reference to the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period in which the performance and/or service conditions are satisfied, ending on the date on which the relevant employees become fully entitled to the award (the “vesting period”). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The expense or income recognized in profit or loss represents the change between the cumulative expense recognized at the end of the reporting period and the cumulative expense recognized at the end of the previous reporting period. No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied. If the Company modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date. F. Loss per share The Company presents basic and diluted loss per share for its ordinary shares. Basic loss per share is calculated by dividing the loss attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is determined by adjusting the loss attributable to holders of ordinary shares of the Company and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. G. Provisions A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement. H. Income tax Income tax includes current and deferred tax. Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. A provision for uncertain tax positions, or reduction in deferred tax asset, is recognized when it is more probable than not that the Company will have to use its economic resources to pay the obligation. Deferred tax is recognized for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that there will be future taxable profits against which such tax benefits can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. As of December 31, 2021, no deferred tax assets have been recorded since it is not probable that the Company will have future taxable income against which any tax losses, benefits or deductible temporary differences can be utilized. I. Financing income and expenses Financing income includes interest income and foreign currency gains or losses and measured in fair value through profit or loss. Interest income is recognized as it accrues using the effective interest method. Financing expense includes mainly bank charges and foreign currency losses. Foreign currency gains and losses on financial assets and financial liabilities are reported on a net basis as either financing income or financing expenses, depending on whether foreign currency movements are in a net gain or net loss position.

Cash

Cash	12 Months Ended
Cash	Dec. 31, 2021
Cash [Abstract]
Cash	Note 4 — Cash December 31, December 31, U.S. dollars U.S. dollars Denominated in NIS $ 693 $ 384 Denominated in USD 10,359 250 Denominated in EUR 4 58 Denominated in GBP 7 7 $ 11,063 $ 699

Other Receivables

Other Receivables	12 Months Ended
Other Receivables	Dec. 31, 2021
Disclosure of trade and other receivables [text block] [Abstract]
Other receivables	Note 5 — Other receivables December 31, December 31, U.S. dollars U.S. dollars Government agencies $ 102 $ 30 Prepaid expenses 132 - Other 76 - $ 310 $ 30

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
Property, Plant and Equipment, Net	Dec. 31, 2021
Disclosure of property, plant and equipment [text block] [Abstract]
Property, plant and equipment, net	Note 6 — Property, plant and equipment, net Balance as of December 31, 2021: Computers and Office Leasehold Total U.S. dollars in thousands Cost: Balance at January 1, 2021 $ 5 2 9 16 Purchases during the year 3 14 - 17 Disposals during the year - - (9 ) (9 ) Balance at December 31, 2021 8 16 - 24 Accumulated depreciation: Balance at January 1, 2021 2 (* ) 1 3 Depreciation during the year 2 1 - 3 Disposals during the year - - (1 ) (1 ) Balance at December 31, 2021 4 1 - 5 Depreciated cost at December 31, 2021 $ 4 $ 15 $ - $ 19 Balance as of December 31, 2020: Computers and Office Leasehold Total U.S. dollars in thousands Cost: Balance at January 1, 2020 $ 1 $ 2 $ 4 $ 7 Purchases during the year 4 — 5 9 Balance at December 31, 2020 5 2 9 16 Accumulated depreciation: Balance at January 1, 2020 (* ) (* ) (* ) (* ) Depreciation during the year 2 (* ) 1 3 Balance at December 31, 2020 2 (* ) 1 3 Depreciated cost at December 31, 2020 $ 3 $ 2 $ 8 $ 13 (*) less than 1 thousand

Other Payables

Other Payables	12 Months Ended
Other Payables	Dec. 31, 2021
Other payables [Abstract]
Other Payables	Note 7 — Other payables December 31, 2021 2020 U.S. dollars U.S. dollars Employees and payroll accruals $ 115 $ 36 Accrued expenses 443 29 $ 558 $ 65

Shareholders' Equity

Shareholders' Equity	12 Months Ended
Shareholders' Equity	Dec. 31, 2021
Disclosure of investments accounted for using equity method [text block] [Abstract]
Shareholders' Equity	Note 8 — Shareholders’ Equity A. Share capital Number of shares Number of shares Authorized Issued and paid 2021 Authorized 2020 Issued and paid 2020 Ordinary shares of no par value 60,000,000 10,943,534 30,000,000 5,582,922 On November 7, 2021, the Company’s shareholders adopted the recommendation of the Company’s board of directors and approved a 1-for-3 split of the Company’s share capital. The implementation of the split on November 9, 2021 resulted in an increase of the issued and outstanding ordinary shares. In addition, the Company’s shareholders also approved a change to the par value of the ordinary shares from NIS 0.001 per share to no par value and an increase the authorized share capital of the Company to 60,000,000 ordinary shares. In these financial statements, all information related to the Company’s ordinary shares and their associated par value, shares options, warrant and associated exercise price have been retroactively adjusted to give effect to the above-mentioned share split and the cancellation of the par value of the Company’s ordinary shares. a. During 2019, the Company entered into Share Purchase Agreements (each, an “SPA”), with several investors pursuant to which the Company issued 488,250 ordinary shares for a total consideration of $405,000. Some of the investors who signed an SPA in 2019 also received a warrant to purchase additional ordinary shares at an exercise price per warrant equal to the price per share of the ordinary shares issued under the applicable SPA. The warrants were exercisable into an aggregate amount of 1,530,000 ordinary shares and for a total consideration of $1,020 thousand. Pursuant to the SPAs, the warrants were exercisable immediately from the closing date of the applicable SPA and were set to expire on December 31, 2020. During 2020, the board of directors extended the expiration period for each option to December 31, 2021 (See also Note 8f below). b. In July 2019, the Company entered into a crowd-funding transaction in which the Company issued 799,998 ordinary shares to 1,116 different investors for a total net consideration of $1,015 thousand (net of $118 thousand issuance costs). c. In February 2020, the Company entered into a second crowd-funding transaction in which the Company issued 370,356 ordinary shares to 536 different investors for total net consideration of $447 thousand (net of $52 thousand issuance cost). d. In April 2020, the Company entered into a third crowd-funding transaction in which the Company issued 47,688 shares to 161 different investors for total net consideration of $61 thousand (net of $8 thousand issuance cost). e. In February, May, June and July 2021, the Company entered into Simple Agreements for Future Equity (each, a “SAFE”) with four separate investors for aggregate proceeds of $800 thousand. Pursuant to the terms of each SAFE, upon consummation of an equity financing, the Company will issue to each investor the number of ordinary shares equal to the purchase amount divided by the SAFE price, which is defined as the price per share equal to 80% of the equity financing valuation (to be no less than $25,000 thousand). The SAFE Agreements also provide the investor the right to automatically receive ordinary shares in the case of a liquidity event, defined as a change of control event or an initial public offering. In the case of a liquidity event the investors are entitled to the number of ordinary shares equal to the investment amount divided by the liquidity price. The liquidity price is defined as the price per share equal to the Company’s valuation at the time of the liquidity event, multiplied by 80%, and divided by the Company’s capitalization (to be no less than $25,000 thousand). As part of Company’s initial public offering (“IPO”) (as described in Note 8i below), the SAFEs were converted at a price per share of $2.892 into 276,672 ordinary shares. For accounting purposes, the SAFE instrument was classified under shareholders’ equity. f. During 2018 and 2019, the Company entered into several Share Purchase Agreements (“SPAs”) with multiple investors pursuant to which the Company issued shares and warrants. Pursuant to the SPAs, the warrants had an exercise price of $0.67 and were set to expire on December 31, 2020. During 2020, the board of directors extended the expiration period for each warrant to December 31, 2021. In September 2021, three of the warrant holders assigned all or part of their warrants to four assignees, among whom are the Company’s CFO and related parties of the Company’s CEO and CFO). In August and September 2021 after the said assignments, the Company received warrant exercise notices of 1,837,500 warrants, out of the total 2,130,000 warrants outstanding at that time. The other 292,500 warrants that were not exercised were waived by their owners. As a result of the said exercises, the Company received aggregate proceeds of $1,225 thousand. g. In May and October 2021, several option holders exercised their outstanding options to purchase 285,000 ordinary shares for a gross proceed of $10 thousand. h. In October 2021, several option holders, holding an aggregate amount of 961,440 options, signed an exercise notice for their options. The proceeds from such options exercise were approximately $76 thousand. As of December 31, 2021, the proceeds from such exercises were recognized as other receivables. i. In December 2021, the Company closed its IPO in the United States and issued 2,000,000 units consisting of 2,000,000 Ordinary shares and 2,000,000 tradable warrants with an exercise price of $6 per share and term of 5 years. In certain cases, the warrants may be exercised on a cashless basis. Therefore, the warrants are accounted for as derivative instruments which are classified as a liability and measured at fair value through profit or loss (refer also to Note 16). The total gross consideration was $12,000 thousand. $4,560 thousand was initially attributed to the warrants based on their fair value and the remaining amount was attributed to the ordinary shares issued and recognized as an equity component in the amount of $7,440 thousand. Applicable issuance costs, amounting to $2,136 thousand, have been allocated in the same proportion as the allocation of the gross proceeds. An amount of $812 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $1,324 thousand have been recorded in equity as a reduction of the share premium. As part of the IPO, the Company also recognized share-based issuance costs of $898 thousand which were allocated in the same proportion as the allocation of the gross proceeds from the IPO, accordingly an amount of $341 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $557 thousand have been recorded in equity as a reduction of the share premium (refer also to Note 9(18)). The total net proceeds from the offering were approximately $9,864 thousand and net proceeds from the exercise of underwriter’s option were $3. The following table summarizes the movement in share capital: Ordinary shares 2021 2020 Issued and paid-in share capital as at January 1 5,582,922 5,164,878 Issued for cash during the period 2,000,000 418,044 Exercise of share warrants and options during the year 3,083,940 - Conversion of SAFE instruments 276,672 - Issued and paid-in share capital as at December 31 10,943,534 5,582,922 B. Ordinary Shares Right Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of shares outstanding.

Share Based Payment

Share Based Payment	12 Months Ended
Share Based Payment	Dec. 31, 2021
Disclosure of share-based payment arrangements [text block] [Abstract]
Share Based Payment	Note 9 — Share Based Payment On December 16, 2018, the Company’s board of directors approved an employee share option plan (“ESOP”). According to the provisions of the ESOP, the exercise period, exercise price and vesting conditions for each option grant will be determined by the board of directors. The number of shares reserved for issuance is subject to Ordinary shares subject to options granted under the 2018 Plan that expire or forfeited or otherwise terminated without having been exercised in full will become available again for future grant under the 2018 Plan. The expiration date of the options granted to employees and directors is after 10 years from the grant date. Relating to options granted to services providers, the expiration date of the options is between 3-10 years from the grant date. In addition, pursuant to the grant letters, the options granted to employees, directors and service providers shall become vested and exercisable upon any merger or consolidation in which the Company is a constituent party as described in the grant letters (“Exit Event”). On October 31, 2021, the Company’s board of directors approved an amendment to the Company’s 2018 Employee Share Option Plan. The amendment determines that the total number of underlying shares reserved for future issuance under the plan and any modification thereof, shall be: ● 900,000 shares, plus ● An annual increase to be added as of the first day of the Company’s fiscal year, beginning in 2022 and occurring each year thereafter through 2032, equal to 4% of the total number of ordinary shares issued and outstanding on a fully-diluted basis as of the end of the Company’s immediately preceding fiscal year (or such lesser number of shares, including no shares, determined by the board of directors in its sole discretion). Following this amendment, the number of shares reserved under this plan was 1,151,130. As of December 31, 2021, 309,630 ordinary shares are available for future grant. 1. In February and April 2019, the Company granted 18,000 options to certain service providers of the Company. The options have an exercise price of $0.03 per share. The options will vest quarterly over two years from the vesting commencement date. 2. In May 2019, the Company granted 126,000 options to an employee of the Company. The options have an exercise price of $0.03 per share. The options will vest quarterly over three years from the vesting commencement date. 3. In May 2019, the Company granted 225,000 options to a director of the Company. The options have an exercise price of $0.03 per share. The first 120,000 options will vest on the first quarter beginning on the vesting commencement date. The remaining options shall vest equally on each subsequent quarter following the first quarter beginning on the vesting commencement date over the following year and three 4. In August 2019, the Company granted 60,000 options to certain directors of the Company. The options have an exercise price of $0.03 per share. The options will vest quarterly over one year commencing January 2020. 5. In January 2020, the Company granted 18,000 options to a service provider of the Company. The options have an exercise price of NIS 5 per share ($1.61 per share, based on the exchange rate reported by the Bank of Israel on December 31, 2021). 50% of the options vest after one year from the grant date and the remaining options vest in four 6. In March 2020, the Company granted 54,000 options to an employee and a service provider of the Company: ● 18,000 options have an exercise price of NIS 5 per share ($1.61 per share, based on the exchange rate reported by the Bank of Israel on December 31, 2021). 50% of the options vest after one year from the vesting commencement date and the remaining options vest in four equal quarterly thereafter. ● 36,000 options have an exercise price of $0.03 per share. 33% of the options vest after one year from the vesting commencement date and the remaining options vest in eight equal quarterly thereafter. 7. In July 2020, the Company granted 24,000 options to certain service providers of the Company. ● 12,000 options have an exercise price of $0.03 per share. 25% of the options vested immediately and the remaining options vest in four equal quarterly thereafter. ● 12,000 options have an exercise price of $0.03 per share. The options vest in four equal quarterly as of the date of grant. 8. In July 2020, the Company granted 12,000 fully vested options to a service provider of the Company. The options have an exercise price of NIS 5 per share ($1.61 per share, based on the exchange rate reported by the Bank of Israel on December 31, 2021). 9. In November and December, 2020, the Company granted 6,000 options to certain service providers of the Company. The options have an exercise price of $0.03 per share. The options vest in four 10. In March 2021, the Company’s board of directors approved the grant of 15,000 options to a certain service provider of the Company. The options had an exercise price of $1.67 per share. The options were to vest quarterly over one year starting June 2021. On October 31, 2021, the Company’s board of directors approved a new grant to such service provider. Accordingly, the Company granted 22,500 options with the following terms: ● 10,500 options have an exercise price of $1.67 per share. The options vest immediately upon an IPO. ● 6,000 options have an exercise price of $1.67 per share. The options vest on December 15, 2021. ● 6,000 options have an exercise price of $1.67 per share. The options will on March 15, 2022. The options are exercisable if the Company receives services from the service provider during the mentioned period. The Company accounted the new grant as a modification to the existing grant. 11. In July 2021, the Company granted 21,000 options to the Company’s chief financial officer. The options have an exercise price of $0.03 per share. The options vest monthly over seven 12. In August 2021, the Company’s board of directors approved the grant of 9,000 options to an employee. The options have an exercise price of $5.33 per share. The options vest quarterly over 3 years starting September 2021. 13. On December 13, 2021, upon the completion of the Company's IPO, 961,440 options were exercised into shares (refer to Note 8h above) and 20,130 Options were expired. Those options previously granted to Company’s service providers, which, according to their grants, are vested upon a successful consummation of the IPO the remaining unrecognized expenses were recorded immediately upon such vesting. 14. On October 31, 2021, the Company’s board of directors recommended that the shareholders approve, and on November 7, 2021 the Company’s shareholders approved the following awards to the Company’s current management and directors subject to an IPO: ● 108,000 RSUs to each of the Company’s Chief Executive Officer and Chief Financial Officer, which vest on a quarterly basis over 3 years, commencing December 13, 2021. ● 192,000 options to the Chairman of the Board. The options vest over four years on a quarterly basis commencing October 1, 2021 at an exercise price equal to $3.51. ● 72,000 options to a director. The options have an exercise price of $3.51 per share. The commencement date of the Option's is December 13, 2021 (the “Vesting Commencement Date”). The Options vest as follows: one-third vest one year from the Commencement Date and the remainder vest quarterly over the following two year period. 15. On October 31, 2021, the Company’s board of directors approved the grant of 108,000 options to the Company’s Chief Medical Officer. The options have an exercise price of $3.51 per share and vest on a quarterly basis over 3 years starting December 2021. 16. On November 9, 2021, the Company’s board of directors approved the extension of the exercise period of options of two employees, which, pursuant to their original terms would have been expire if not exercised before the completion of the IPO. According to the grant letter, at the event of an IPO, all unvested options were fully vested, and accordingly, the remaining unrecognized expenses were recorded immediately upon such vesting. 17. On December 9, 2021, the underwriter (see Note 8i), partially exercised its right to purchase an additional 300,000 warrants for a total consideration of $3 thousands. The warrants have an exercise price of $6 per share and expire 5 years after the issuance date. These warrants were treated as issuance costs, which amounted to $681 thousand based on third party valuation, and have been allocated in the same proportion as the allocation of the gross proceeds from the IPO. An amount of $259 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $422 thousand have been recorded in equity as a reduction of the share premium. Furthermore, as part of the offering, the Company issued 100,000 warrants to the underwriters as share-based issuance costs . The warrants have an exercise price of $7.5 per share and expire 5 years after date of issuance and can be exercised after June 8, 2022. These options were treated as issuance costs, which amounted to $217 thousand based on third party valuation, and have been allocated in the same proportion as the allocation of the gross proceeds from the IPO. An amount of $82 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $135 thousand have been recorded in equity as a reduction of the share premium. The fair value was estimated at the grant date using Binominal option pricing model for employees and directors and Black-Scholes option pricing model for service providers, taking into account the terms and conditions upon which the share options were granted. For determination of the share price used in those option pricing models — the Company used different approaches as further detailed below. The fair value of RSUs was estimated by multiplying the number of RSUs granted by share price as of grant date. The following table lists the inputs used for calculation of fair value of the options granted to employees and directors for the years ended December 31, 2021, 2020 and 2019: 2021 2020 2019 Expected volatility 91.60%-95.01% 94.00% 90.48%-93.02% Exercise price 0.03-5.33 0.03 0.03 Share price (1) 3.72-18.65 1.06 1.06-1.08 Risk-free interest rate 1.42%-1.81% 1% 1.54%-2.48% Dividend yield 0 0 0 Expected life 10 10 10 The following table lists the inputs used for calculation of fair value of the options granted to consultants for the years ended December 31, 2021, 2020 and 2019: 2021 2020 2019 Expected volatility 89.92%-97.18% 87.05%-93.98% 91.48%-94.16 Exercise price 0.03-1.67 0.03-1.44 0.03 Share price (1) 2.46-18.67 1.06-6.96 0.23-1.07 Risk-free interest rate 1.25%-1.72 % 0.21%-1.95% 2.09%-2.95% Dividend yield 0 0 0 Expected life (years) 6.15-10 3-10 8.54-10 (1) Share price for options granted during January 2019 - September 2020 was determined based on the implied share price in recent capital raising and for grants after that date, in light of significant achievements in clinical trials and absence of recent fundraising reflecting embodying the said achievements, was calculated using discounted cash flows model, with the following assumptions: projected revenues, projected operating expenses, projected EBITDA margin, projected taxes on income, weighted-average cost of capital of 30%. From October 2021, the Company determined its value based on two scenarios: a stay private scenario (which included a private M&A transaction) and an IPO scenario. The DCF method was used to determine the Company's value for the stay private scenario and for the IPO scenario, the value was determined based on underwriters' indication for the possible range of the share price in the anticipated IPO. The Hybrid Method was utilized to allocate the Company's value appropriately to determine the fair value of its ordinary shares. The Hybrid Method considered the following future liquidity event scenarios: (1) a stay private scenario (which included a private M&A transaction) and (2) an IPO scenario applying a probability weighting of 60% and 40% to the stay private and the IPO scenarios, respectively, after considering the Company’s stage of development, the stage of IPO discussions and potential volatility in the market. The following table lists the inputs used for calculation of fair value of the underwriters warrants granted: Expected volatility 90.59% Exercise price $7.5 Share price (1) $3.72 Risk-free interest rate 1.23% Dividend yield 0 Expected life 5 The following table summarizes the share option activity for the annual periods ended on December 31, 2021 and 2020: Number of Weighted average Options outstanding at January 1, 2021 1,476,570 $ 0.08 Granted 424,500 $ 3.28 Expired (20,130 ) 0.03 Exercised (1,246,440 ) 0.07 Options outstanding at December 31, 2021 634,500 $ 2.25 Exercisable at December 31, 2021 231,749 0.47 Number of Weighted average Options outstanding at January 1, 2020 1,362,570 $ 0.03 Granted 114,000 0.67 Options outstanding at December 31, 2020 1,476,570 $ 0.08 Exercisable at December 31, 2020 1,040,547 As discussed in Note 9(14), during 2021 the Company granted 216,000 RSU’s to its officers. As of December 31, 2021, all of such RSUs were outstanding (out of which, none are exercisable as of December 31, 2021). As of December 31, 2021, the Company also granted 100,000 warrants to the underwriters as non cash issuance cost compensation and the underwriter has exercised his option and purchased 300,000 warrants (refer to Note 9(18)). These warrants are still outstanding as of December 31, 2021. The share-based expense recognized in the statements of income were as follows: For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Share-based compensation expense – Research and development $ 1,969 $ 1,804 474 Share-based compensation expense – General and administrative 1,849 257 137 Share-based compensation expense – Finance expenses 341 - - $ 4,159 $ 2,061 611 In addition, to the share-based compensation expenses that have been recorded in profit and loss, share-based compensation in the amount of $557 has been allocated to the issuance of shares and accordingly recorded as a reduction of the share premium.

Research and Development Expens

Research and Development Expenses	12 Months Ended
Research and Development Expenses	Dec. 31, 2021
Disclosure of research and development expense [text block] [Abstract]
Research and development expenses	Note 10 — Research and development expenses For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Subcontractors and consultants $ 628 $ 452 $ 304 Share-based compensation 1,969 1,804 474 Salaries and social benefits 447 227 105 Others 38 12 15 $ 3,082 $ 2,495 $ 898

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
General and Administrative Expenses	Dec. 31, 2021
General and Administrative Expenses [Abstract]
General and Administrative Expenses	Note 11 — General and Administrative Expenses For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Professional services $ 372 $ 49 $ 111 Share-based compensation 1,849 257 137 Salaries and social benefits 74 52 56 Insurance 68 14 6 Traveling abroad 50 8 24 Others 92 13 3 $ 2,505 $ 393 $ 337

Finance Income, Net

Finance Income, Net	12 Months Ended
Finance Income, Net	Dec. 31, 2021
Disclosure of finance income (cost) [text block] [Abstract]
Finance Income, Net	Note 12 — Finance Income, net For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Finance Income: Revaluation of warrants $ 2,732 $ - $ - Exchange rates - 61 18 $ 2,732 $ 61 $ 18 Finance Expenses: Issuance costs $ (1,152 ) $ - $ - Exchange rates (32 ) - - Bank fees (2 ) (1 ) (5 ) $ (1,186 ) $ (1 ) $ (5 ) Total financing income, net $ 1,546 $ 60 $ 13

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
Commitment and Contingencies	Dec. 31, 2021
Commitment and Contingencies [Abstract]
Commitment and contingencies	Note 13 — Commitment and contingencies In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent payments including utilities amount to approximately $7 thousand. The lease period is for 24 months with an option to extend the lease period for additional two periods of 12 months each.

Related Parties Balances and Tr

Related Parties Balances and Transactions	12 Months Ended
Related Parties Balances and Transactions	Dec. 31, 2021
Related Parties Balances and Transactions [Abstract]
Related Parties Balances and Transactions	Note 14 — Related Parties Balances and Transactions A. Balances with related parties: As of December 31, 2021 2020 U.S. dollars in thousands Other payables – Officers and Directors $ 65 $ 13 $ 65 $ 13 B. Transactions with related parties: For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Salary fees (1) $ 257 $ 126 $ 112 Directors consultancy fees (2) 29 28 27 Share based payment expense (refer to Note 9) 1,707 66 230 $ 1,993 $ 220 $ 369 (1) Number of related parties 3 1 1 (2) Number of directors 4 4 4 C. Transactions with related parties 1. On April 22, 2019, the Company entered into an assignment agreement with its chief executive officer, pursuant to which he assigned the Company the full and exclusive rights to an invention in the United States, and any and all patents which may be granted in the United States related to the methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases. The Company paid one dollar as consideration for the assignment. As the transaction has been performed with a controlling shareholder, the Company measured the transferred assets at the nominal amount paid. 2. During 2019, some the financing transactions disclosed in note A above have been performed with persons that are family members of the Company's chief executive officer. These transactions were carried out on the same terms as other investors. 3. On June 1, 2021, the Company signed an employee agreement with its Chief Financial Officer according to which the Company will pay a monthly fee for his services. In addition, as part of the agreement, Chief Financial Officer was granted with 21,000 options (refer to Note 9(11)). Under the employment agreement, it was agreed that to the extent that economical value of the Options at such time that the Company consummates it’s IPO (the “Options Valuation”) will be, in the aggregate, less than US$ 200 thousand, then the Company shall allocate to the Employee additional Options equal, in the aggregate, to the difference between the Options Valuation and US$ 200 thousand. 4. On October 31, 2021, the Company’s board of directors recommended that the shareholders approve, and on November 7, 2021 the Company’s shareholders approved, among others, the following: ● Compensation packages for the Company’s executive officers, consisting of (i) an annual base salary payable in cash and (ii) a target annual bonus based on a combination of Company performance and personal goals and (iii) share based compensation (refer to Note 9(14)). ● Compensation package for the chairman and other independent and external directors, consisting of (i) an annual retainer payable in cash, (ii) additional cash retainers for committee chairmanship and committee service, and (iii) share based compensation (refer to Note 9(14)).

Loss Per Share

Loss Per Share	12 Months Ended
Loss Per Share	Dec. 31, 2021
Disclosure of earnings per share [text block] [Abstract]
Loss Per Share	Note 15 — Loss Per Share Basic loss per share is computed by dividing the loss for the period applicable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. For the years ended December 31, 2021, 2020 and 2019, all outstanding share options have been excluded from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented. The loss and the weighted average number of shares used in computing basic and diluted net loss per share is as follows (U.S. dollars in thousands, except share and per share data): For the year ended December 31, 2021 2020 2019 Numerator: Net loss applicable to shareholders of ordinary shares (in Thousands) (4,041 ) (2,828 ) (1,222 ) Denominator: Shares of ordinary share used in computing basic and diluted net loss per share 6,243,411 5,519,061 4,634,043 Net loss per share of ordinary share, basic and diluted (0.65 ) (0.51 ) (0.26 )

Financial Instruments

Financial Instruments	12 Months Ended
Financial Instruments	Dec. 31, 2021
Financial Instruments [Abstract]
Financial Instruments	Note 16 — Financial Instruments The Company has exposure to the following risks from its use of financial instruments: ● Credit risk ● Liquidity risk ● Market risk This note presents quantitative and qualitative information about the Company’s exposure to each of the above risks, and the Company’s objectives, policies and processes for measuring and managing risk. The carrying amounts of cash and cash equivalents, other receivables, restricted deposits, trade payables, and other payables approximate their fair value due to the short-term maturities of such instruments. Credit risk The Company’s credit risk arises principally from the Company’s cash The Company holds cash with banks and financial institutions and in the estimation of management, the credit risk for these financial instruments is low. Liquidity risk The cash surpluses held by the Company that are not required for financing its current activity, are invested in interest-bearing investment channels such as: short-term deposits. This investment channels are chosen by the Company’s managements based on future forecasts of the cash the Company will require in order to meet its liabilities. Cash flow forecasts are determined on an individual basis. The Company examines current forecasts of its liquidity requirements so as to make certain that there is sufficient cash for its operating needs. The following are the contractual maturities of financial liabilities at undiscounted amounts and based on the future rates forecasted at the reporting date: December 31, 2021 Carrying amount Contractual cash flows 6 months or less U.S. dollars in thousands Non-derivative financial liabilities Trade payables 39 39 39 Other payables 548 548 548 December 31, 2020 Carrying amount Contractual cash flows 6 months or less U.S. dollars in thousands Non-derivative financial liabilities Trade payables 55 55 55 Other payables 65 65 65 Market risk The Company is exposed to foreign exchange risk resulting from the exposure to different currencies, mainly the NIS. Foreign exchange risk arises on recognized assets and liabilities that are denominated in a foreign currency other than the functional currency. The Company acts to reduce the foreign exchange risk by managing an adequate part of the available liquid sources in or linked to the NIS. December 31, 2021 Foreign currency Dollar NIS Euro GBP Total U.S. dollars in thousands Financial assets and financial liabilities: Assets: Cash 10,359 693 4 7 11,063 Other receivables - 210 100 - 310 Restricted deposits - 39 - - 39 Liabilities: Trade payables 39 - - - 39 Other payables 200 358 - - 558 Liability in respect of warrants 1,828 - - - 1,828 Total net exposure in statement of financial position in respect of financial assets and financial liabilities 8,292 584 104 7 8,987 December 31, 2020 Foreign currency Dollar NIS Euro GBP Total U.S. dollars in thousands Financial assets and financial liabilities: Assets: Cash 250 384 58 7 699 Other receivables — 30 — — 30 Restricted deposits — 37 — — 37 Liabilities: Trade payables 20 27 6 2 55 Other payables 6 59 — — 65 Total net exposure in statement of financial position in respect of financial assets and financial liabilities 224 365 52 5 646 Sensitivity analysis A change as of December 31, 2021 in the exchange rates of the following currencies against the dollar, as indicated below would have affected the measurement of financial instruments denominated in a foreign currency and would have increased (decreased) profit or loss and equity by the amounts shown below. This analysis is based on foreign currency exchange rate that the Company considered to be reasonably possible at the end of the reporting period. The analysis assumes that all other variables remain constant. The analysis was performed on the same basis for 2020. December 31, 2021 Increase Decrease Profit or loss Equity Profit or loss Equity U.S. dollars in thousands Change in the exchange rate of: 10% in the NIS 58 58 (58 ) (58 ) 10% in the GBP 1 1 (1 ) (1 ) 10% in the Euro 10 10 (10 ) (10 ) December 31, 2020 Increase Decrease Profit or loss Equity Profit or loss Equity U.S. dollars in thousands Change in the exchange rate of: 10% in the NIS 37 37 (37 ) (37 ) 10% in the GBP 1 1 (1 ) (1 ) 10% in the Euro 5 5 (5 ) (5 ) D. Fair value of financial instruments The carrying amounts of certain financial assets and liabilities, including cash, trade receivables, other receivables, trade payables and other payables are the same or proximate to their fair value. As part of the IPO (refer to Note 8A(i)), the Company issued 2,000,000 warrants to investors. At the grant date and December 31, 2021, the Company measured their fair value and the changes in fair value were recognized in profit or loss. The fair value of the liability in respect to the warrants at their issuance date (December 13, 2021) was determined by using the Monte-Carlo model (fair value measurement at level 2), and as of the end of the year according to the warrant price at the stock market (fair value measurement at level 1). The table below presents an analysis of the fair value of the liability in respect to the warrants at their issuance date (December 13, 2021) and at the end of the year: December 13, December 31, Thousands Thousands Financial liabilities: Warrants 4,560 1,828 Total 4,560 1,828 Details regarding fair value measurement at Levels 2 The fair value of the warrants was measured using the Monte-Carlo model. The following inputs were used to determine the fair value: December 13, Expected volatility (a) 90.61 % Share price (d) 3.72 Risk-free interest rate (b) 1.30 Expected life (years) (c) 5 (a) Based on the historical volatility of comparable companies. (b) Based on traded zero-coupon U.S. treasury bonds with maturity equal to expected terms. (c) Based on contractual terms. (d) Derived from the issuance of the equity units issued in Company’s IPO.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2021
Disclosure of income tax [text block] [Abstract]
Income Taxes	Note 17 — Income Taxes A. Details regarding the tax environment of the Company (1) Corporate tax rate The tax rate relevant to the Company in the years 2021, 2020 and 2019 was 23%. B. Unrecognized deferred tax assets As of December 31, 2021, the Company had carried forward losses for tax purposes in the amount of approximately $3,960 thousand. Under current tax regulation in Israel, tax losses do not expire. The Company has not recorded deferred tax assets with respect to carry forward losses nor in respect of other timing differences such as research and development expenses carried forward and other timing differences in the amount of $3,100 thousand, because there is a low level of certainty that such losses or temporary deductible differences will be utilized in the foreseeable future. C. Tax assessments The Company has not received tax assessments since its inception date. D. The main reconciling item between the statutory tax rate of the Company and the effective tax rate is current year tax losses and benefits for which no deferred tax assets were created.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2021
Disclosure of events after reporting period [text block] [Abstract]
Subsequent Events	Note 18 — Subsequent Events On January 25, 2022 and March 10, 2022, the Company’s board of directors and shareholders, respectively, approved the compensation of each of the Company's external directors and a newly appointed director. Such compensation included the grant of 72,000 options to each such director at an exercise price of $1.43 per share, pursuant to the Company’s 2018 Employee Share Option Plan. One-third of each option award vests one year from the grant date and the remainder vests quarterly and becomes fully vested three years from the grant date. On January 25, 2022, the Company’s board of directors approved the grant of aggregate amount of 192,000 options to several employees. The options have an exercise price of $2.18 per share. The options vest quarterly over 3 years starting January 25, 2022. In March 2022, the Company received an amount of $3,870 thousand as a result of the exercise of 645,000 warrants at a price per share of $6. On March 31 2022, the Company’s board of directors approved the grant of aggregate amount of 36,000 options to several employees. The options have an exercise price of $3.97 per share. The options vest quarterly over 3 years starting March 31, 2022.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Dec. 31, 2021
Accounting Policies [Abstract]
Property, plant and equipment	A. Property, plant and equipment (1) Recognition and measurement Property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. Gain and loss on disposal of a property, plant and equipment item is determined by comparing the net proceeds from disposal with the carrying amount of the asset, and is recognized in profit or loss. (2) Subsequent costs The cost of replacing property, plant and equipment and other subsequent expenses are capitalized if it is probable that the future economic benefits associated with them will flow to the Company and their cost can be measured reliably. (3) Depreciation Depreciation is a systematic allocation of the depreciable amount of an asset over its useful life. The depreciable amount is the cost of the asset, or other amount substituted for cost, less its residual value. An asset is depreciated from the date it is ready for use, meaning the date it reaches the location and condition required for it to operate in the manner intended by management. Depreciation is recognized in profit or loss on a straight-line basis over the estimated useful lives of each part of the property, plant and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Annual depreciation rates are: % Computers and peripherals and equipment 33 Office furniture and equipment 7 – 15 Leasehold improvements The shorter of the lease term and the useful life Depreciation methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate.
Financial instruments	B. Financial instruments (1) Non-derivative financial assets Initial recognition of financial assets Financial assets are recognized initially on the trade date at which the Company becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Company to the cash flows from the asset expire, or the Company transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset were transferred. When the Company retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: amortized cost; fair value through other comprehensive income — investments in debt instruments; fair value through other comprehensive income — investments in equity instruments; or fair value through profit or loss. The Company has balances of other receivables and deposits that are held within a business model whose objective is collecting contractual cash flows. The contractual cash flows of these financial assets represent solely payments of principal and interest that reflect consideration for the time value of money and the credit risk. Accordingly, these financial assets are measured at amortized cost. The Company does not expect to incur any credit loss, thus the financial statements do not include provision for expected credit loss. Subsequent measurement and gains and losses Financial assets at amortized cost These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss. (2) Non-derivative financial liabilities Non-derivative financial liabilities include trade and other payables. Initial recognition of financial liabilities Financial liabilities are recognized initially on the trade date at which the Company becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Transaction costs directly attributable to an expected issuance of an instrument that will be classified as a financial liability are recognized as an asset in the framework of deferred expenses in the statement of financial position. These transaction costs are deducted from the financial liability upon its initial recognition or are amortized as financing expenses in the statement of profit or loss and when the issuance is no longer expected to occur. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Company, as specified in the agreement, expires or when it is discharged or cancelled. Offset of financial instruments Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Issuance of parcel of securities The consideration received from the issuance of a parcel of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the parcel, as described above. (3) Derivative financial liabilities Measurement of derivative financial instruments Derivatives are recognized initially at fair value. Attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognized in profit or loss, as financing income or expense. (4) Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.
Research and Development	C. Research and Development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures, including patent registration costs, are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. As of December 31, 2021, no development expenditures have met the recognition criteria and thus the Company expensed all of its development expenditures as incurred.
Impairment of non-financial assets	D. Impairment of non-financial assets Assets that are subject to depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped together into the smallest group of assets that generates separately identifiable cash flows (cash-generating units). The carrying amounts of the Company’s non-financial assets reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated.
Employee benefits	E. Employee benefits (1) Post-employment benefits The Company’s liability for severance pay for its employees is calculated pursuant to Israeli Severance Pay Law (1963) (the “Severance Pay Law”). The Company’s liability is covered by monthly deposits with severance pay funds and insurance policies. For all of the Company’s employees, the payments to pension funds and to insurance companies exempt the Company from any obligation towards its employees, in accordance with Section 14 of the Severance Pay Law, which is accounted for as a defined contribution plan. Accumulated amounts in pension funds and in insurance companies are not under the Company’s control or management and, accordingly, neither those amounts nor the corresponding accrual for severance pay are presented in the statements of financial position. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Contributions to a defined contribution plan that are due more than 12 months after the end of the period in which the employees render the service are discounted to their present value. (2) Share based payment The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at the grant date. The fair value is determined using an acceptable option pricing model. As for other service providers, the cost of each transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration for equity instruments cannot be measured, such goods or services are measured by reference to the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period in which the performance and/or service conditions are satisfied, ending on the date on which the relevant employees become fully entitled to the award (the “vesting period”). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The expense or income recognized in profit or loss represents the change between the cumulative expense recognized at the end of the reporting period and the cumulative expense recognized at the end of the previous reporting period. No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied. If the Company modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.
Loss per share	F. Loss per share The Company presents basic and diluted loss per share for its ordinary shares. Basic loss per share is calculated by dividing the loss attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is determined by adjusting the loss attributable to holders of ordinary shares of the Company and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares.
Provisions	G. Provisions A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.
Income tax	H. Income tax Income tax includes current and deferred tax. Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. A provision for uncertain tax positions, or reduction in deferred tax asset, is recognized when it is more probable than not that the Company will have to use its economic resources to pay the obligation. Deferred tax is recognized for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that there will be future taxable profits against which such tax benefits can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. As of December 31, 2021, no deferred tax assets have been recorded since it is not probable that the Company will have future taxable income against which any tax losses, benefits or deductible temporary differences can be utilized.
Financing income and expenses	I. Financing income and expenses Financing income includes interest income and foreign currency gains or losses and measured in fair value through profit or loss. Interest income is recognized as it accrues using the effective interest method. Financing expense includes mainly bank charges and foreign currency losses. Foreign currency gains and losses on financial assets and financial liabilities are reported on a net basis as either financing income or financing expenses, depending on whether foreign currency movements are in a net gain or net loss position.

Basis of Preparation (Tables)

Basis of Preparation (Tables)	12 Months Ended
Basis of Preparation (Tables)	Dec. 31, 2021
Basis of Preparation [Abstract]
Schedule of regarding the exchange rate of the New Israeli Shekel	Euro GBP NIS December 31, 2021 1.13 1.35 0.32 December 31, 2020 1.22 1.36 0.31 December 31, 2019 1.12 1.32 0.29 Change in percentages: Year ended December 31, 2021 (7.3 ) (0.73 ) 3.2 Year ended December 31, 2020 9.3 3.5 7.5 Year ended December 31, 2019 (2 ) 3.2 8.4

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
Significant Accounting Policies (Tables)	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Schedule of annual depreciation rates	% Computers and peripherals and equipment 33 Office furniture and equipment 7 – 15 Leasehold improvements The shorter of the lease term and the useful life

Cash (Tables)

Cash (Tables)	12 Months Ended
Cash (Tables)	Dec. 31, 2021
Cash [Abstract]
Schedule of cash	December 31, December 31, U.S. dollars U.S. dollars Denominated in NIS $ 693 $ 384 Denominated in USD 10,359 250 Denominated in EUR 4 58 Denominated in GBP 7 7 $ 11,063 $ 699

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
Other Receivables (Tables)	Dec. 31, 2021
Disclosure of trade and other receivables [text block] [Abstract]
Schedule of other receivables	December 31, December 31, U.S. dollars U.S. dollars Government agencies $ 102 $ 30 Prepaid expenses 132 - Other 76 - $ 310 $ 30

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
Property, Plant and Equipment, Net (Tables)	Dec. 31, 2021
Disclosure of property, plant and equipment [text block] [Abstract]
Schedule of property, plant and equipment, net	Computers and Office Leasehold Total U.S. dollars in thousands Cost: Balance at January 1, 2021 $ 5 2 9 16 Purchases during the year 3 14 - 17 Disposals during the year - - (9 ) (9 ) Balance at December 31, 2021 8 16 - 24 Accumulated depreciation: Balance at January 1, 2021 2 (* ) 1 3 Depreciation during the year 2 1 - 3 Disposals during the year - - (1 ) (1 ) Balance at December 31, 2021 4 1 - 5 Depreciated cost at December 31, 2021 $ 4 $ 15 $ - $ 19 Computers and Office Leasehold Total U.S. dollars in thousands Cost: Balance at January 1, 2020 $ 1 $ 2 $ 4 $ 7 Purchases during the year 4 — 5 9 Balance at December 31, 2020 5 2 9 16 Accumulated depreciation: Balance at January 1, 2020 (* ) (* ) (* ) (* ) Depreciation during the year 2 (* ) 1 3 Balance at December 31, 2020 2 (* ) 1 3 Depreciated cost at December 31, 2020 $ 3 $ 2 $ 8 $ 13 (*) less than 1 thousand

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
Other Payables (Tables)	Dec. 31, 2021
Other payables [Abstract]
Schedule of other payables	December 31, 2021 2020 U.S. dollars U.S. dollars Employees and payroll accruals $ 115 $ 36 Accrued expenses 443 29 $ 558 $ 65

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
Shareholders' Equity (Tables)	Dec. 31, 2021
Disclosure of investments accounted for using equity method [text block] [Abstract]
Schedule of share capital	Number of shares Number of shares Authorized Issued and paid 2021 Authorized 2020 Issued and paid 2020 Ordinary shares of no par value 60,000,000 10,943,534 30,000,000 5,582,922
Schedule of summarizes the movement in share capital	Ordinary shares 2021 2020 Issued and paid-in share capital as at January 1 5,582,922 5,164,878 Issued for cash during the period 2,000,000 418,044 Exercise of share warrants and options during the year 3,083,940 - Conversion of SAFE instruments 276,672 - Issued and paid-in share capital as at December 31 10,943,534 5,582,922

Share Based Payment (Tables)

Share Based Payment (Tables)	12 Months Ended
Share Based Payment (Tables)	Dec. 31, 2021
Disclosure of share-based payment arrangements [text block] [Abstract]
Schedule of fair value of the options granted	2021 2020 2019 Expected volatility 91.60%-95.01% 94.00% 90.48%-93.02% Exercise price 0.03-5.33 0.03 0.03 Share price (1) 3.72-18.65 1.06 1.06-1.08 Risk-free interest rate 1.42%-1.81% 1% 1.54%-2.48% Dividend yield 0 0 0 Expected life 10 10 10 2021 2020 2019 Expected volatility 89.92%-97.18% 87.05%-93.98% 91.48%-94.16 Exercise price 0.03-1.67 0.03-1.44 0.03 Share price (1) 2.46-18.67 1.06-6.96 0.23-1.07 Risk-free interest rate 1.25%-1.72 % 0.21%-1.95% 2.09%-2.95% Dividend yield 0 0 0 Expected life (years) 6.15-10 3-10 8.54-10
Schedule of fair value of the underwriters warrants granted	Expected volatility 90.59% Exercise price $7.5 Share price (1) $3.72 Risk-free interest rate 1.23% Dividend yield 0 Expected life 5
Schedule of summarizes the share option activity	Number of Weighted average Options outstanding at January 1, 2021 1,476,570 $ 0.08 Granted 424,500 $ 3.28 Expired (20,130 ) 0.03 Exercised (1,246,440 ) 0.07 Options outstanding at December 31, 2021 634,500 $ 2.25 Exercisable at December 31, 2021 231,749 0.47 Number of Weighted average Options outstanding at January 1, 2020 1,362,570 $ 0.03 Granted 114,000 0.67 Options outstanding at December 31, 2020 1,476,570 $ 0.08 Exercisable at December 31, 2020 1,040,547
Schedule of share-based expense recognized in the statements of income	For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Share-based compensation expense – Research and development $ 1,969 $ 1,804 474 Share-based compensation expense – General and administrative 1,849 257 137 Share-based compensation expense – Finance expenses 341 - - $ 4,159 $ 2,061 611

Research and Development Expe_2

Research and Development Expenses (Tables)	12 Months Ended
Research and Development Expenses (Tables)	Dec. 31, 2021
Disclosure of research and development expense [text block] [Abstract]
Schedule of research and development expenses	For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Subcontractors and consultants $ 628 $ 452 $ 304 Share-based compensation 1,969 1,804 474 Salaries and social benefits 447 227 105 Others 38 12 15 $ 3,082 $ 2,495 $ 898

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
General and Administrative Expenses (Tables)	Dec. 31, 2021
General and Administrative Expenses [Abstract]
Schedule of general and administrative expenses	For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Professional services $ 372 $ 49 $ 111 Share-based compensation 1,849 257 137 Salaries and social benefits 74 52 56 Insurance 68 14 6 Traveling abroad 50 8 24 Others 92 13 3 $ 2,505 $ 393 $ 337

Finance Income, Net (Tables)

Finance Income, Net (Tables)	12 Months Ended
Finance Income, Net (Tables)	Dec. 31, 2021
Disclosure of finance income (cost) [text block] [Abstract]
Schedule of finance income ,net	For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Finance Income: Revaluation of warrants $ 2,732 $ - $ - Exchange rates - 61 18 $ 2,732 $ 61 $ 18 Finance Expenses: Issuance costs $ (1,152 ) $ - $ - Exchange rates (32 ) - - Bank fees (2 ) (1 ) (5 ) $ (1,186 ) $ (1 ) $ (5 ) Total financing income, net $ 1,546 $ 60 $ 13

Related Parties Balances and _2

Related Parties Balances and Transactions (Tables)	12 Months Ended
Related Parties Balances and Transactions (Tables)	Dec. 31, 2021
Related Parties Balances and Transactions [Abstract]
Schedule of balances with related parties	As of December 31, 2021 2020 U.S. dollars in thousands Other payables – Officers and Directors $ 65 $ 13 $ 65 $ 13
Schedule of transactions with related parties	For the year ended December 31, 2021 2020 2019 U.S. dollars in thousands Salary fees (1) $ 257 $ 126 $ 112 Directors consultancy fees (2) 29 28 27 Share based payment expense (refer to Note 9) 1,707 66 230 $ 1,993 $ 220 $ 369 (1) Number of related parties 3 1 1 (2) Number of directors 4 4 4

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
Loss Per Share (Tables)	Dec. 31, 2021
Disclosure of earnings per share [text block] [Abstract]
Schedule of computing basic and diluted net loss per share	For the year ended December 31, 2021 2020 2019 Numerator: Net loss applicable to shareholders of ordinary shares (in Thousands) (4,041 ) (2,828 ) (1,222 ) Denominator: Shares of ordinary share used in computing basic and diluted net loss per share 6,243,411 5,519,061 4,634,043 Net loss per share of ordinary share, basic and diluted (0.65 ) (0.51 ) (0.26 )

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
Financial Instruments (Tables)	Dec. 31, 2021
Financial Instruments [Abstract]
Schedule of contractual maturities of financial liabilities at undiscounted amounts	December 31, 2021 Carrying amount Contractual cash flows 6 months or less U.S. dollars in thousands Non-derivative financial liabilities Trade payables 39 39 39 Other payables 548 548 548 December 31, 2020 Carrying amount Contractual cash flows 6 months or less U.S. dollars in thousands Non-derivative financial liabilities Trade payables 55 55 55 Other payables 65 65 65
Schedule of acts to reduce the foreign exchange risk	December 31, 2021 Foreign currency Dollar NIS Euro GBP Total U.S. dollars in thousands Financial assets and financial liabilities: Assets: Cash 10,359 693 4 7 11,063 Other receivables - 210 100 - 310 Restricted deposits - 39 - - 39 Liabilities: Trade payables 39 - - - 39 Other payables 200 358 - - 558 Liability in respect of warrants 1,828 - - - 1,828 Total net exposure in statement of financial position in respect of financial assets and financial liabilities 8,292 584 104 7 8,987 December 31, 2020 Foreign currency Dollar NIS Euro GBP Total U.S. dollars in thousands Financial assets and financial liabilities: Assets: Cash 250 384 58 7 699 Other receivables — 30 — — 30 Restricted deposits — 37 — — 37 Liabilities: Trade payables 20 27 6 2 55 Other payables 6 59 — — 65 Total net exposure in statement of financial position in respect of financial assets and financial liabilities 224 365 52 5 646
Schedule of analysis is based on foreign currency exchange rate	December 31, 2021 Increase Decrease Profit or loss Equity Profit or loss Equity U.S. dollars in thousands Change in the exchange rate of: 10% in the NIS 58 58 (58 ) (58 ) 10% in the GBP 1 1 (1 ) (1 ) 10% in the Euro 10 10 (10 ) (10 ) December 31, 2020 Increase Decrease Profit or loss Equity Profit or loss Equity U.S. dollars in thousands Change in the exchange rate of: 10% in the NIS 37 37 (37 ) (37 ) 10% in the GBP 1 1 (1 ) (1 ) 10% in the Euro 5 5 (5 ) (5 )
Schedule of analysis of the fair value of liability to warrants issuance	December 13, December 31, Thousands Thousands Financial liabilities: Warrants 4,560 1,828 Total 4,560 1,828
Schedule of fair value of the warrants was measured using the monte-carlo model	December 13, Expected volatility (a) 90.61 % Share price (d) 3.72 Risk-free interest rate (b) 1.30 Expected life (years) (c) 5

Basis of Preparation (Details)

Basis of Preparation (Details) - Schedule of regarding the exchange rate of the New Israeli Shekel	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Euro [Member]
Basis of Preparation (Details) - Schedule of regarding the exchange rate of the New Israeli Shekel [Line Items]
Exchange rate	1.13	1.22	1.12
Change in percentages exchange rate	(7.3)	9.3	(2)
GBP [Member]
Basis of Preparation (Details) - Schedule of regarding the exchange rate of the New Israeli Shekel [Line Items]
Exchange rate	1.35	1.36	1.32
Change in percentages exchange rate	(0.73)	3.5	3.2
NIS [Member]
Basis of Preparation (Details) - Schedule of regarding the exchange rate of the New Israeli Shekel [Line Items]
Exchange rate	0.32	0.31	0.29
Change in percentages exchange rate	3.2	7.5	8.4

Significant Accounting Polici_3

Significant Accounting Policies (Details) - Schedule of annual depreciation rates	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Computers and peripherals and equipment	33.00%
Leasehold improvements	The shorter of the lease term and the useful life
Bottom of Range [Member]
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Office furniture and equipment	7.00%
Top of Range [Member]
Significant Accounting Policies (Details) - Schedule of annual depreciation rates [Line Items]
Office furniture and equipment	15.00%

Cash (Details) - Schedule of ca

Cash (Details) - Schedule of cash - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash (Details) - Schedule of cash [Line Items]
Cash	$ 11,063	$ 699
NIS [Member]
Cash (Details) - Schedule of cash [Line Items]
Cash	693	384
USD [Member]
Cash (Details) - Schedule of cash [Line Items]
Cash	10,359	250
EUR [Member]
Cash (Details) - Schedule of cash [Line Items]
Cash	4	58
GBP [Member]
Cash (Details) - Schedule of cash [Line Items]
Cash	$ 7	$ 7

Other Receivables (Details) - S

Other Receivables (Details) - Schedule of other receivables - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of other receivables [Abstract]
Government agencies	$ 102	$ 30
Prepaid expenses	132
Other	76
Total	$ 310	$ 30

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Cost:
Cost opening balance		$ 16	$ 7
Purchases during the year		17	9
Disposals during the year		(9)
Cost ending balance		24	16
Accumulated depreciation:
Accumulated depreciation opening balance		3		[1]
Depreciation during the year		3	3
Disposals during the year		(1)
Accumulated depreciation ending balance		5	3
Depreciated cost		19	13
Computers and peripherals and equipment [Member]
Cost:
Cost opening balance		5	1
Purchases during the year		3	4
Disposals during the year
Cost ending balance		8	5
Accumulated depreciation:
Accumulated depreciation opening balance		2		[1]
Depreciation during the year		2	2
Disposals during the year
Accumulated depreciation ending balance		4	2
Depreciated cost		4	3
Office furniture and equipment [Member]
Cost:
Cost opening balance		2	2
Purchases during the year		14
Disposals during the year
Cost ending balance		16	2
Accumulated depreciation:
Accumulated depreciation opening balance	[1]
Depreciation during the year		1		[1]
Disposals during the year
Accumulated depreciation ending balance		1		[1]
Depreciated cost		15	2
Leasehold improvements [Member]
Cost:
Cost opening balance		9	4
Purchases during the year			5
Disposals during the year		(9)
Cost ending balance			9
Accumulated depreciation:
Accumulated depreciation opening balance		1		[1]
Depreciation during the year			1
Disposals during the year		(1)
Accumulated depreciation ending balance			1
Depreciated cost			$ 8

[1]	less than 1 thousand

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of other payables - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of other payables [Abstract]
Employees and payroll accruals	$ 115	$ 36
Accrued expenses	443	29
Total other payables	$ 558	$ 65

Shareholders' Equity (Details)

Shareholders' Equity (Details) $ / shares in Units, $ in Thousands	Nov. 07, 2021₪ / sharesshares	Oct. 31, 2021USD ($)shares	May 31, 2021shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Disclosure of investments accounted for using equity method [text block] [Abstract]
Reduction of per share of per ordinary share (in New Shekels per share) \| ₪ / shares	₪ 0.001
Number of ordinary shares (in Shares) \| shares	60,000,000		285,000	2,000,000
Share purchase agreement, description				a.During 2019, the Company entered into Share Purchase Agreements (each, an “SPA”), with several investors pursuant to which the Company issued 488,250 ordinary shares for a total consideration of $405,000. Some of the investors who signed an SPA in 2019 also received a warrant to purchase additional ordinary shares at an exercise price per warrant equal to the price per share of the ordinary shares issued under the applicable SPA. The warrants were exercisable into an aggregate amount of 1,530,000 ordinary shares and for a total consideration of $1,020 thousand. Pursuant to the SPAs, the warrants were exercisable immediately from the closing date of the applicable SPA and were set to expire on December 31, 2020. During 2020, the board of directors extended the expiration period for each option to December 31, 2021 (See also Note 8f below). b.In July 2019, the Company entered into a crowd-funding transaction in which the Company issued 799,998 ordinary shares to 1,116 different investors for a total net consideration of $1,015 thousand (net of $118 thousand issuance costs). c.In February 2020, the Company entered into a second crowd-funding transaction in which the Company issued 370,356 ordinary shares to 536 different investors for total net consideration of $447 thousand (net of $52 thousand issuance cost). d.In April 2020, the Company entered into a third crowd-funding transaction in which the Company issued 47,688 shares to 161 different investors for total net consideration of $61 thousand (net of $8 thousand issuance cost). e.In February, May, June and July 2021, the Company entered into Simple Agreements for Future Equity (each, a “SAFE”) with four separate investors for aggregate proceeds of $800 thousand. Pursuant to the terms of each SAFE, upon consummation of an equity financing, the Company will issue to each investor the number of ordinary shares equal to the purchase amount divided by the SAFE price, which is defined as the price per share equal to 80% of the equity financing valuation (to be no less than $25,000 thousand). The SAFE Agreements also provide the investor the right to automatically receive ordinary shares in the case of a liquidity event, defined as a change of control event or an initial public offering. In the case of a liquidity event the investors are entitled to the number of ordinary shares equal to the investment amount divided by the liquidity price. The liquidity price is defined as the price per share equal to the Company’s valuation at the time of the liquidity event, multiplied by 80%, and divided by the Company’s capitalization (to be no less than $25,000 thousand). As part of Company’s initial public offering (“IPO”) (as described in Note 8i below), the SAFEs were converted at a price per share of $2.892 into 276,672 ordinary shares. For accounting purposes, the SAFE instrument was classified under shareholders’ equity.
Exercise price per share (in Dollars per share) \| $ / shares				$ 0.67
Warrants to investors description				In August and September 2021 after the said assignments, the Company received warrant exercise notices of 1,837,500 warrants, out of the total 2,130,000 warrants outstanding at that time. The other 292,500 warrants that were not exercised were waived by their owners. As a result of the said exercises, the Company received aggregate proceeds of $1,225 thousand.
Gross proceed		$ 10
Aggregate share amount (in Shares) \| shares		961,440
Proceeds from options exercise		$ 76		$ 1,238
Shares issued (in Shares) \| shares				2,000,000
Tradable warrants (in Shares) \| shares				2,000,000
Warrants exercise price per share (in Dollars per share) \| $ / shares				$ 6
Total gross consideration				$ 12,000
Warrants based on fair value				4,560
Equity component amount				7,440
Issuance of cost				$ 2,136
Issuance of cost description				An amount of $812 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $1,324 thousand have been recorded in equity as a reduction of the share premium. As part of the IPO, the Company also recognized share-based issuance costs of $898 thousand which were allocated in the same proportion as the allocation of the gross proceeds from the IPO, accordingly an amount of $341 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $557 thousand have been recorded in equity as a reduction of the share premium (refer also to Note 9(18)).
Net proceeds from offering				$ 9,864
Exercise of underwriter’s option (in Dollars per share) \| $ / shares				$ 3

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Schedule of share capital - shares	Dec. 31, 2021	Dec. 31, 2020
Schedule of share capital [Abstract]
Number of shares authorized	60,000,000	30,000,000
Number of shares Issued and paid	10,943,534	5,582,922

Shareholders' Equity (Details_2

Shareholders' Equity (Details) - Schedule of summarizes the movement in share capital - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of summarizes the movement in share capital [Abstract]
Issued and paid-in share capital	5,582,922	5,164,878
Issued for cash during the period	2,000,000	418,044
Exercise of share warrants and options during the year	3,083,940
Conversion of SAFE instruments	276,672
Issued and paid-in share capital	10,943,534	5,582,922

Share Based Payment (Details)

Share Based Payment (Details) - USD ($)

Dec. 13, 2021

Dec. 09, 2021

Dec. 16, 2018

Oct. 31, 2021

Aug. 31, 2021

Jul. 31, 2021

Mar. 31, 2021

Dec. 31, 2020

Nov. 30, 2020

Jul. 31, 2020

Mar. 31, 2020

Jan. 31, 2020

Aug. 31, 2019

May 31, 2019

Apr. 30, 2019

Feb. 28, 2019

Dec. 31, 2021

Share Based Payment (Details) [Line Items]

Description of employee share option plan

●900,000
shares, plus●An annual increase to be added as of the first day of
the Company’s fiscal year, beginning in 2022 and occurring each year thereafter through 2032, equal to 4% of the total number of
ordinary shares issued and outstanding on a fully-diluted basis as of the end of the Company’s immediately preceding fiscal year
(or such lesser number of shares, including no shares, determined by the board of directors in its sole discretion).

Shares reserved

1,151,130

Ordinary shares future grant

309,630

Number of shares options granted

108,000

21,000

12,000

Exercise price per share (in Dollars per share)

$ 3.51

$ 0.03

$ 1.61

Stock option vest term

3 years

7 months

Stock option granted share price description

●10,500 options have an exercise price of $1.67 per share. The
options vest immediately upon an IPO.
●6,000 options have an exercise price of $1.67 per share. The
options vest on December 15, 2021.
●6,000 options have an exercise price of $1.67 per share. The
options will on March 15, 2022.

Grant options value (in Dollars)

$ 200,000

Options which were exercised

961,440

Options were expired shares

20,130

Directors and management description

●108,000 RSUs to each of the Company’s
Chief Executive Officer and Chief Financial Officer, which vest on a quarterly basis over 3 years, commencing December 13, 2021. ●192,000 options to the Chairman of the Board. The options vest over four years on a quarterly basis commencing October 1, 2021 at an exercise price equal to $3.51.

Warrant and underwriters description

On December 9, 2021, the underwriter (see Note 8i), partially exercised its right to purchase an additional 300,000 warrants for a total consideration of $3 thousands. The warrants have an exercise price of $6 per share and expire 5 years after the issuance date. These warrants were treated as issuance costs, which amounted to $681 thousand based on third party valuation, and have been allocated in the same proportion as the allocation of the gross proceeds from the IPO. An amount of $259 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $422 thousand have been recorded in equity as a reduction of the share premium.Furthermore, as part of the offering, the Company issued
100,000 warrants to the underwriters as share-based issuance costs . The warrants have an exercise price of $7.5 per share and expire
5 years after date of issuance and can be exercised after June 8, 2022. These options were treated as issuance costs, which amounted to
$217 thousand based on third party valuation, and have been allocated in the same proportion as the allocation of the gross proceeds from
the IPO. An amount of $82 thousand was considered as issuance costs allocated to the warrants and has been recorded in profit or loss
as finance expense, while costs allocated as issuance costs of ordinary shares in the amount of $135 thousand have been recorded in equity
as a reduction of the share premium.

the Company also granted 100,000
warrants to the underwriters as non cash issuance cost compensation and the underwriter has exercised his option and purchased 300,000
warrants (refer to Note 9(18)). These warrants are still outstanding as of December 31, 2021.

Cost of capital percentage

30.00%

Private transaction description

The Hybrid Method considered the following future liquidity event scenarios: (1) a stay private
scenario (which included a private M&A transaction) and (2) an IPO scenario applying a probability weighting of 60% and 40% to the
stay private and the IPO scenarios, respectively, after considering the Company’s stage of development, the stage of IPO discussions
and potential volatility in the market.

Share based compensation amount (in Dollars)

$ 557

Options Granted to Service Providers [Member]

Share Based Payment (Details) [Line Items]

Number of shares options granted

22,500

15,000

6,000

24,000

18,000

Exercise price per share (in Dollars per share)

$ 1.67

$ 0.03

$ 1.61

$ 0.03

Stock option vest term

4 years

1 year

2 years

Options vest percentage

50.00%

Stock option vest term thereafter

4 months

Options granted to service providers description

25%
of the options vested immediately and the remaining options vest in four equal quarterly thereafter.●12,000 options have an exercise price of $0.03 per share. The
options vest in four equal quarterly as of the date of grant.

Options Granted to Employee [Member]

Share Based Payment (Details) [Line Items]

Number of shares options granted

9,000

54,000

126,000

Exercise price per share (in Dollars per share)

$ 5.33

$ 0.03

Stock option vest term

3 years

Options granted to an employee description

●18,000 options have an exercise price of NIS 5 per share ($1.61
per share, based on the exchange rate reported by the Bank of Israel on December 31, 2021). 50% of the options vest after one year from
the vesting commencement date and the remaining options vest in four equal quarterly thereafter.●36,000 options have an exercise price of $0.03 per share. 33%
of the options vest after one year from the vesting commencement date and the remaining options vest in eight equal quarterly thereafter.

Options Granted to Director [Member]

Share Based Payment (Details) [Line Items]

Number of shares options granted

60,000

225,000

72,000

Exercise price per share (in Dollars per share)

$ 0.03

$ 3.51

Stock option vest term

1 year

3 years

Share vest options

120,000

Bottom of Range [Member]

Share Based Payment (Details) [Line Items]

Grant date

3 years

Top of range [Member]

Share Based Payment (Details) [Line Items]

Grant date

10 years

2018 Plan [Member]

Share Based Payment (Details) [Line Items]

Percentage of share issued

4.00%

Percentage of share outstanding

4.00%

Grant date

10 years

Restricted Stock Units [Member]

Share Based Payment (Details) [Line Items]

Number of shares options granted

216,000

Share Based Payment (Details) -

Share Based Payment (Details) - Schedule of fair value of the options granted - $ / shares		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employees and Directors [Member]
Share Based Payment (Details) - Schedule of fair value of the options granted [Line Items]
Exercise price (in Dollars per share)				$ 0.03
Share price	[1]
Dividend yield		0.00%		0.00%
Expected life		10		10
Employees and Directors [Member] \| Bottom of Range [Member]
Share Based Payment (Details) - Schedule of fair value of the options granted [Line Items]
Expected volatility		91.60%	94.00%	90.48%
Exercise price (in Dollars per share)		$ 0.03	$ 0.03
Share price	[1]	3.72	1.06	1.06
Risk-free interest rate		1.42%	1.00%	1.54%
Dividend yield			0.00%
Expected life			10
Employees and Directors [Member] \| Top of Range [Member]
Share Based Payment (Details) - Schedule of fair value of the options granted [Line Items]
Expected volatility		95.01%		93.02%
Exercise price (in Dollars per share)		$ 5.33
Share price	[1]	18.65		1.08
Risk-free interest rate		1.81%		2.48%
Options Granted to Consultants [Member]
Share Based Payment (Details) - Schedule of fair value of the options granted [Line Items]
Exercise price (in Dollars per share)				$ 0.03
Share price	[1]
Dividend yield		0.00%	0.00%	0.00%
Options Granted to Consultants [Member] \| Bottom of Range [Member]
Share Based Payment (Details) - Schedule of fair value of the options granted [Line Items]
Expected volatility		89.92%	87.05%	91.48%
Exercise price (in Dollars per share)		$ 0.03	$ 0.03
Share price	[1]	2.46	1.06	0.23
Risk-free interest rate		1.25%	0.21%	2.09%
Expected life		6.15	3	8.54
Options Granted to Consultants [Member] \| Top of Range [Member]
Share Based Payment (Details) - Schedule of fair value of the options granted [Line Items]
Expected volatility		97.18%	93.98%	94.16%
Exercise price (in Dollars per share)		$ 1.67	$ 1.44
Share price	[1]	18.67	6.96	1.07
Risk-free interest rate		1.72%	1.95%	2.95%
Expected life		10	10	10

[1]	Share price for options granted during January 2019 - September 2020 was determined based on the implied share price in recent capital raising and for grants after that date, in light of significant achievements in clinical trials and absence of recent fundraising reflecting embodying the said achievements, was calculated using discounted cash flows model, with the following assumptions: projected revenues, projected operating expenses, projected EBITDA margin, projected taxes on income, weighted-average cost of capital of 30%. From October 2021, the Company determined its value based on two scenarios: a stay private scenario (which included a private M&A transaction) and an IPO scenario. The DCF method was used to determine the Company's value for the stay private scenario and for the IPO scenario, the value was determined based on underwriters' indication for the possible range of the share price in the anticipated IPO. The Hybrid Method was utilized to allocate the Company's value appropriately to determine the fair value of its ordinary shares. The Hybrid Method considered the following future liquidity event scenarios: (1) a stay private scenario (which included a private M&A transaction) and (2) an IPO scenario applying a probability weighting of 60% and 40% to the stay private and the IPO scenarios, respectively, after considering the Company’s stage of development, the stage of IPO discussions and potential volatility in the market.

Share Based Payment (Details)_2

Share Based Payment (Details) - Schedule of fair value of the underwriters warrants granted - Underwriters Warrants [Member] - Bottom of Range [Member]	12 Months Ended
	Dec. 31, 2021USD ($)$ / shares
Share Based Payment (Details) - Schedule of fair value of the underwriters warrants granted [Line Items]
Expected volatility	90.59%
Exercise price (in Dollars per share) \| $ / shares	$ 7.5
Share price (in Dollars) \| $	$ 3,720	[1]
Risk-free interest rate	1.23%
Dividend yield	0.00%
Expected life	5 years

[1]	Share price for options granted during January 2019 - September 2020 was determined based on the implied share price in recent capital raising and for grants after that date, in light of significant achievements in clinical trials and absence of recent fundraising reflecting embodying the said achievements, was calculated using discounted cash flows model, with the following assumptions: projected revenues, projected operating expenses, projected EBITDA margin, projected taxes on income, weighted-average cost of capital of 30%. From October 2021, the Company determined its value based on two scenarios: a stay private scenario (which included a private M&A transaction) and an IPO scenario. The DCF method was used to determine the Company's value for the stay private scenario and for the IPO scenario, the value was determined based on underwriters' indication for the possible range of the share price in the anticipated IPO. The Hybrid Method was utilized to allocate the Company's value appropriately to determine the fair value of its ordinary shares. The Hybrid Method considered the following future liquidity event scenarios: (1) a stay private scenario (which included a private M&A transaction) and (2) an IPO scenario applying a probability weighting of 60% and 40% to the stay private and the IPO scenarios, respectively, after considering the Company’s stage of development, the stage of IPO discussions and potential volatility in the market.

Share Based Payment (Details)_3

Share Based Payment (Details) - Schedule of summarizes the share option activity	12 Months Ended
	Dec. 31, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares
Number of options [Member]
Share Based Payment (Details) - Schedule of summarizes the share option activity [Line Items]
Number of options, Options outstanding Beginning balance	1,476,570	1,362,570
Number of options ,Granted	424,500	114,000
Number of options, Expired	(20,130)
Number of options, Exercised	(1,246,440)
Number of options, Options outstanding Ending balance	634,500	1,476,570
Number of options, Exercisable	231,749	1,040,547
Weighted average exercise price [Member]
Share Based Payment (Details) - Schedule of summarizes the share option activity [Line Items]
Weighted average exercise price, Options outstanding Beginning balance (in Dollars per share) \| $ / shares	$ 0.08	$ 0.03
Weighted average exercise price, Granted (in Dollars per share) \| $ / shares	3.28	0.67
Weighted average exercise price, Expired (in Dollars per share) \| $ / shares	$ 0.03
Weighted average exercise price, Exercised	0.07
Weighted average exercise price, Options outstanding Ending balance (in Dollars per share) \| $ / shares	$ 2.25	$ 0.08
Weighted average exercise price, Exercisable (in Dollars per share) \| $ / shares	$ 0.47

Share Based Payment (Details)_4

Share Based Payment (Details) - Schedule of share-based expense recognized in the statements of income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Payment (Details) - Schedule of share-based expense recognized in the statements of income [Line Items]
General and administrative	$ 2,505	$ 393	$ 337
Total share-based expense	4,159	2,061	611
Share-based compensation expense [Member]
Share Based Payment (Details) - Schedule of share-based expense recognized in the statements of income [Line Items]
Research and development	1,969	1,804	474
General and administrative	1,849	$ 257	$ 137
Finance expenses	$ 341

Research and Development Expe_3

Research and Development Expenses (Details) - Schedule of research and development expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of research and development expenses [Abstract]
Subcontractors and consultants	$ 628	$ 452	$ 304
Share-based compensation	1,969	1,804	474
Salaries and social benefits	447	227	105
Others	38	12	15
Research and development expenses, total	$ 3,082	$ 2,495	$ 898

General and Administrative Ex_3

General and Administrative Expenses (Details) - Schedule of general and administrative expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of general and administrative expenses [Abstract]
Professional services	$ 372	$ 49	$ 111
Share-based compensation	1,849	257	137
Salaries and social benefits	74	52	56
Insurance	68	14	6
Traveling abroad	50	8	24
Others	92	13	3
Total	$ 2,505	$ 393	$ 337

Finance Income, Net (Details) -

Finance Income, Net (Details) - Schedule of finance income,net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finance Income:
Revaluation of warrants	$ 2,732
Exchange rates		61	18
Finance income gross	2,732	61	18
Finance Expenses:
Issuance costs	(1,152)
Exchange rates	(32)
Bank fees	(2)	(1)	(5)
Finance income expenses gross	(1,186)	(1)	(5)
Total financing income, net	$ 1,546	$ 60	$ 13

Commitment and Contingencies (D

Commitment and Contingencies (Details) $ in Thousands	12 Months Ended
Commitment and Contingencies (Details) $ in Thousands	Dec. 31, 2021USD ($)
Commitment and Contingencies [Abstract]
Monthly rent payments	$ 7

Related Parties Balances and _3

Related Parties Balances and Transactions (Details)	Jun. 01, 2021
Related Parties Balances and Transactions [Abstract]
Employee agreement, description	the Company signed an employee agreement with its Chief Financial Officer according to which the Company will pay a monthly fee for his services. In addition, as part of the agreement, Chief Financial Officer was granted with 21,000 options (refer to Note 9(11)). Under the employment agreement, it was agreed that to the extent that economical value of the Options at such time that the Company consummates it’s IPO (the “Options Valuation”) will be, in the aggregate, less than US$ 200 thousand, then the Company shall allocate to the Employee additional Options equal, in the aggregate, to the difference between the Options Valuation and US$ 200 thousand.

Related Parties Balances and _4

Related Parties Balances and Transactions (Details) - Schedule of balances with related parties - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of balances with related parties [Abstract]
Other payables – Officers and Directors	$ 65	$ 13
Balance of related parties, total	$ 65	$ 13

Related Parties Balances and _5

Related Parties Balances and Transactions (Details) - Schedule of transactions with related parties - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of transactions with related parties [Abstract]
Salary fees	[1]	$ 257	$ 126	$ 112
Directors consultancy fees	[2]	29	28	27
Share based payment expense (refer to Note 9)		1,707	66	230
Transactions with related parties, total		1,993	220	369
Number of related parties	[1]	3	1	1
Number of directors	[2]	$ 4	$ 4	$ 4

[1]	Number of related parties
[2]	Number of directors

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of computing basic and diluted net loss per share - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss applicable to shareholders of ordinary shares (in Thousands)	(4,041)	(2,828)	(1,222)
Denominator:
Shares of ordinary share used in computing basic and diluted net loss per share	6,243,411	5,519,061	4,634,043
Net loss per share of ordinary share, basic and diluted (in Dollars per share)	$ (0.65)	$ (0.51)	$ (0.26)

Financial Instruments (Details)

Financial Instruments (Details)	12 Months Ended
Financial Instruments (Details)	Dec. 31, 2021shares
Initial Public Offering [Member]
Financial Instruments (Details) [Line Items]
Warrants shares issued	2,000,000

Financial Instruments (Detail_2

Financial Instruments (Details) - Schedule of contractual maturities of financial liabilities at undiscounted amounts - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Carrying Amount [Member]
Non-derivative financial liabilities
Trade payables	$ 39	$ 55
Other payables	548	65
Contractual cash flows [Member]
Non-derivative financial liabilities
Trade payables	39	55
Other payables	548	65
6 months or less [Member]
Non-derivative financial liabilities
Trade payables	39	55
Other payables	$ 548	$ 65

Financial Instruments (Detail_3

Financial Instruments (Details) - Schedule of acts to reduce the foreign exchange risk - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Assets:
Cash	$ 11,063	$ 699
Other receivables	310	30
Restricted deposits	39	37
Liabilities:
Trade payables	39	55
Other payables	558	65
Liability in respect of warrants	1,828
Total net exposure in statement of financial position in respect of financial assets and financial liabilities	8,987	646
Dollar [Member]
Assets:
Cash	10,359	250
Other receivables
Restricted deposits
Liabilities:
Trade payables	39	20
Other payables	200	6
Liability in respect of warrants	1,828
Total net exposure in statement of financial position in respect of financial assets and financial liabilities	8,292	224
NIS [Member]
Assets:
Cash	693	384
Other receivables	210	30
Restricted deposits	39	37
Liabilities:
Trade payables		27
Other payables	358	59
Total net exposure in statement of financial position in respect of financial assets and financial liabilities	584	365
Euro [Member]
Assets:
Cash	4	58
Other receivables	100
Restricted deposits
Liabilities:
Trade payables		6
Other payables
Liability in respect of warrants
Total net exposure in statement of financial position in respect of financial assets and financial liabilities	104	52
GBP [Member]
Assets:
Cash	7	7
Other receivables
Restricted deposits
Liabilities:
Trade payables		2
Other payables
Liability in respect of warrants
Total net exposure in statement of financial position in respect of financial assets and financial liabilities	$ 7	$ 5

Financial Instruments (Detail_4

Financial Instruments (Details) - Schedule of analysis is based on foreign currency exchange rate - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
NIS [Member] \| Top of Range [Member]
Financial Instruments (Details) - Schedule of analysis is based on foreign currency exchange rate [Line Items]
Profit or loss	$ 58	$ 37
Equity	58	37
NIS [Member] \| Bottom of Range [Member]
Financial Instruments (Details) - Schedule of analysis is based on foreign currency exchange rate [Line Items]
Profit or loss	(58)	(37)
Equity	(58)	(37)
GBP [Member] \| Top of Range [Member]
Financial Instruments (Details) - Schedule of analysis is based on foreign currency exchange rate [Line Items]
Profit or loss	1	1
Equity	1	1
GBP [Member] \| Bottom of Range [Member]
Financial Instruments (Details) - Schedule of analysis is based on foreign currency exchange rate [Line Items]
Profit or loss	(1)	(1)
Equity	(1)	(1)
Euro [Member] \| Top of Range [Member]
Financial Instruments (Details) - Schedule of analysis is based on foreign currency exchange rate [Line Items]
Profit or loss	10	5
Equity	10	5
Euro [Member] \| Bottom of Range [Member]
Financial Instruments (Details) - Schedule of analysis is based on foreign currency exchange rate [Line Items]
Profit or loss	(10)	(5)
Equity	$ (10)	$ (5)

Financial Instruments (Detail_5

Financial Instruments (Details) - Schedule of analysis of the fair value of liability to warrants issuance - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 13, 2021
Financial liabilities:
Warrants	$ 1,828	$ 4,560
Total	$ 1,828	$ 4,560

Financial Instruments (Detail_6

Financial Instruments (Details) - Schedule of fair value of the warrants was measured using the monte-carlo model	12 Months Ended
	Dec. 31, 2021$ / shares
Schedule of fair value of the warrants was measured using the monte-carlo model [Abstract]
Expected volatility	90.61%	[1]
Share price (in Dollars per share)	$ 3.72	[2]
Risk-free interest rate	1.30%	[3]
Expected life (years)	5 years	[4]

[1]	Based on the historical volatility of comparable companies.
[2]	Derived from the issuance of the equity units issued in Company’s IPO.
[3]	Based on traded zero-coupon U.S. treasury bonds with maturity equal to expected terms.
[4]	Based on contractual terms.

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes (Details) [Line Items]
Tax rate percentage	23.00%	23.00%	23.00%
Tax amount (in Dollars)	$ 3,960
Research and development expenses [Member]
Income Taxes (Details) [Line Items]
Research and development expenses (in Dollars)	$ 3,100

Subsequent Events (Details)

Subsequent Events (Details) - Major ordinary share transactions [member] - $ / shares	Mar. 10, 2022	Jan. 25, 2022	Mar. 31, 2022
Subsequent Events (Details) [Line Items]
Compensation option granted shares	72,000	72,000
Exercise price per share (in Dollars per share)	$ 1.43	$ 1.43	$ 6
Aggregate amount of shares		192,000	3,870,000
Excise price per share (in Dollars per share)		$ 2.18
Warrants			645,000
Board of directors [Member]
Subsequent Events (Details) [Line Items]
Aggregate amount of shares			36,000
Board of Directors [Member]
Subsequent Events (Details) [Line Items]
Exercise price per share (in Dollars per share)			$ 3.97